S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NASDAQ:RGLS

Regulus Therapeutics - RGLS Stock Forecast, Price & News

$1.69
-0.02 (-1.17%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.64
$1.70
50-Day Range
$1.37
$1.85
52-Week Range
$1.33
$4.00
Volume
15,799 shs
Average Volume
35,448 shs
Market Capitalization
$24.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.67

Regulus Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
649.5% Upside
$12.67 Price Target
Short Interest
Healthy
1.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.29mentions of Regulus Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.23) to ($2.06) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

332nd out of 1,047 stocks

Pharmaceutical Preparations Industry

144th out of 512 stocks

RGLS stock logo

About Regulus Therapeutics (NASDAQ:RGLS) Stock

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Receive RGLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RGLS Stock News Headlines

13 Best Biotech Penny Stocks To Buy Now
Earnings Outlook For Regulus Therapeutics
Regulus Therapeutics to Participate in Upcoming...
See More Headlines
Receive RGLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RGLS Company Calendar

Last Earnings
11/10/2021
Today
12/02/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/09/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:RGLS
CUSIP
75915K10
Fax
N/A
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.67
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+649.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-27,810,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10.01 million
Book Value
$2.71 per share

Miscellaneous

Free Float
13,421,000
Market Cap
$24.72 million
Optionable
Optionable
Beta
1.66

Key Executives

  • Mr. Joseph P. Hagan M.B.A.Mr. Joseph P. Hagan M.B.A. (Age 53)
    Pres, CEO & Director
    Comp: $868.25k
  • Ms. Crispina Calsada CPA (Age 52)
    Chief Financial Officer
    Comp: $481.01k
  • Mr. Christopher Ray Aker J.D.Mr. Christopher Ray Aker J.D. (Age 61)
    Sr. VP, Gen. Counsel & Corp. Sec.
    Comp: $509.22k
  • Mr. Daniel J. Penksa (Age 36)
    Sr. Director of Fin. & Controller
  • Dr. Denis Drygin Ph.D. (Age 48)
    Chief Scientific Officer
  • Mr. Firuz Shakoori
    Head of CMC













RGLS Stock - Frequently Asked Questions

Should I buy or sell Regulus Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RGLS shares.
View RGLS analyst ratings
or view top-rated stocks.

What is Regulus Therapeutics' stock price forecast for 2023?

4 analysts have issued twelve-month price objectives for Regulus Therapeutics' stock. Their RGLS share price forecasts range from $9.00 to $20.00. On average, they anticipate the company's share price to reach $12.67 in the next year. This suggests a possible upside of 649.5% from the stock's current price.
View analysts price targets for RGLS
or view top-rated stocks among Wall Street analysts.

How have RGLS shares performed in 2022?

Regulus Therapeutics' stock was trading at $3.15 on January 1st, 2022. Since then, RGLS shares have decreased by 46.3% and is now trading at $1.69.
View the best growth stocks for 2022 here
.

When is Regulus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our RGLS earnings forecast
.

How were Regulus Therapeutics' earnings last quarter?

Regulus Therapeutics Inc. (NASDAQ:RGLS) announced its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by $0.20. During the same period in the previous year, the company earned ($0.40) earnings per share.

When did Regulus Therapeutics' stock split?

Regulus Therapeutics shares reverse split on Wednesday, June 29th 2022. The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Joseph Hagan's approval rating as Regulus Therapeutics' CEO?

2 employees have rated Regulus Therapeutics Chief Executive Officer Joseph Hagan on Glassdoor.com. Joseph Hagan has an approval rating of 49% among the company's employees. This puts Joseph Hagan in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Regulus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regulus Therapeutics investors own include Aduro Biotech (ADRO), Flexion Therapeutics (FLXN), Cytori Therapeutics (CYTX), PTC Therapeutics (PTCT), Novavax (NVAX), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP) and Trevena (TRVN).

What is Regulus Therapeutics' stock symbol?

Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS."

Who are Regulus Therapeutics' major shareholders?

Regulus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.93%), BlackRock Inc. (0.31%), Commonwealth Equity Services LLC (0.23%) and Dimensional Fund Advisors LP (0.22%). Insiders that own company stock include Christopher Ray Aker, Denis Drygin, Joseph P Hagan and Paul Edward Walker.
View institutional ownership trends
.

How do I buy shares of Regulus Therapeutics?

Shares of RGLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regulus Therapeutics' stock price today?

One share of RGLS stock can currently be purchased for approximately $1.69.

How much money does Regulus Therapeutics make?

Regulus Therapeutics (NASDAQ:RGLS) has a market capitalization of $24.73 million and generates $10.01 million in revenue each year. The biopharmaceutical company earns $-27,810,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis.

How can I contact Regulus Therapeutics?

Regulus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The official website for the company is www.regulusrx.com. The biopharmaceutical company can be reached via phone at (858) 202-6300 or via email at ccalsada@regulusrx.com.

This page (NASDAQ:RGLS) was last updated on 12/2/2022 by MarketBeat.com Staff